70 active not recruiting. 70 Phase 2, 13 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 70 | Active not recruiting 70 |
| Phase 1 | 13 | Active not recruiting 13 |
Follow Myeloproliferative Disorders: new trials by email Literature Review of Myeloproliferative Disorders trials Research Report on Myeloproliferative Disorders
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy of Asciminib in Chronic Phase CML Patients With T315I Mutations asciminib 200 mg BID - Chronic Myeloid Leukemia (CML) | Phase 2 | Active not recruiting | Thomas Ernst, PD Dr. med. | 50 | 2026-06-22 | 2026-08-27 |
| A Phase 2, Open-Label Study of DISC-3405 in Participants With Polycythemia Vera (PV) DISC-3405 - Polycythemia Vera (PV) | Phase 2 | Active not recruiting | Disc Medicine, Inc | 60 | 2025-08-12 | 2026-07-31 |
| Improving Treatment Outcomes in Chronic Myeloid Leukaemia Patients Using Imatinib and Artesunate Combination Therapy Imatinib, Artesunate - Chronic Myeloid Leukemia (CML) | Phase 2 | Active not recruiting | Obafemi Awolowo University | 75 | 2025-07-01 | 2026-10-14 |
| A First-in-Human Study of HLA-Partially to Fully Matched Allogenic Cryopreserved Deceased Donor Bone Marrow Transplantation for Patients With Hematologic Malignancies Ossium HPC Marrow, Bone Marrow Transplant, Pre-transplant conditioning - Myeloablative (MAC), Pre-transplant conditioning - Reduced Intensity (RIC) - Acute Leukemia, Acute Lymphoblastic Leukemia | Phase 1 / Phase 2 | Active not recruiting | Ossium Health, Inc. | 12 | 2024-08-16 | 2026-09-10 |
| HLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation With Reduced Dose Post Transplantation Cyclophosphamide GvHD Prophylaxis Busulfan, Fludarabine, PBSC Hematopoietic Stem Cell Transplantation (HSCT) - Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia | Phase 2 | Active not recruiting | Center for International Blood and Marrow Transplant Research | 313 | 2023-12-08 | 2026-08-17 |
| Azacitidine Combined With Venetoclax in Patients With Higher-risk Chronic Myelomonocytic Leukemia (AVENHIR) Venetoclax - Chronic Myeloid Leukemia | Phase 2 | Active not recruiting | Groupe Francophone des Myelodysplasies | 44 | 2023-10-04 | 2026-09-29 |
| Venetoclax in Combination With ASTX727 for the Treatment of Chronic Myelomonocytic Leukemia and Other Myelodysplastic Syndrome/Myeloproliferative Neoplasm Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 132 | 2023-06-27 | 2026-08-19 |
| Cord Blood Transplant in Adults With Blood Cancers Conditioning Chemotherapy, Cord blood graft - Acute Myelogenous Leukemia (AML), Acute Lymphoblastic Leukemia (ALL) | Phase 2 | Active not recruiting | Memorial Sloan Kettering Cancer Center | 17 | 2023-05-22 | 2026-10-23 |
| Luspatercept for Anemia in Lower Risk MDS or Non-proliferative MDS/MPN Neoplasms Luspatercept - Myelodysplastic Syndromes, Myeloproliferative Neoplasm | Phase 2 | Active not recruiting | H. Lee Moffitt Cancer Center and Research Institute | 6 | 2023-02-21 | 2026-05-05 |
| Study to Assess SLN124 in Patients With Polycythemia Vera SLN124, Placebo - Polycythemia Vera | Phase 1 / Phase 2 | Active not recruiting | Silence Therapeutics plc | 69 | 2023-01-26 | 2025-12-19 |
| Adding Itacitinib to Cyclophosphamide and Tacrolimus for the Prevention of Graft Versus Host Disease in Patients Undergoing Hematopoietic Stem Cell Transplants Cyclophosphamide, Itacitinib, Peripheral Blood Stem Cell Transplantation - Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia | Phase 2 | Active not recruiting | City of Hope Medical Center | 20 | 2022-12-29 | 2026-10-14 |
| Asciminib Monotherapy, With Dose Escalation, for 2nd and 1st Line Chronic Myelogenous Leukemia asciminib - Chronic Myelogenous Leukemia - Chronic Phase | Phase 2 | Active not recruiting | Novartis Pharmaceuticals | 34 | 2022-11-11 | 2025-10-14 |
| A Single-arm, Multicenter Study to Assess the Efficacy, Safety, and Tolerability of P1101 in Adults With ET Ropeginterferon alfa-2b-njft (P1101) - Essential Thrombocythemia | Phase 2 | Active not recruiting | PharmaEssentia | 91 | 2022-09-29 | 2025-08-13 |
| Comparing the Addition of an Anti-Cancer Drug, Pomalidomide, to the Usual Chemotherapy Treatment (Daunorubicin and Cytarabine Liposome) in Newly Diagnosed Acute Myeloid Leukemia With Myelodysplastic Syndrome-Related Changes Biospecimen Collection, Bone Marrow Aspiration and Biopsy, Liposome-encapsulated Daunorubicin-Cytarabine - Acute Myeloid Leukemia, Acute Myeloid Leukemia Post Cytotoxic Therapy | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 49 | 2022-08-24 | 2026-06-30 |
| Study of Canakinumab in Patients With Myelofibrosis Canakinumab - Primary Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis | Phase 2 | Active not recruiting | John Mascarenhas | 14 | 2022-08-02 | 2026-05-07 |
| Infusion of Expanded Cord Blood Cells in Addition to Single Cord Blood Transplant in Treating Patients With Acute Leukemia, Chronic Myeloid Leukemia, or Myelodysplastic Syndromes Dilanubicel, Cyclophosphamide, Fludarabine - Acute Biphenotypic Leukemia, Acute Lymphoblastic Leukemia | Phase 2 | Active not recruiting | Fred Hutchinson Cancer Center | 31 | 2022-05-10 | 2026-07-10 |
| Asciminib as Initial Therapy for Patients With Chronic Myeloid Leukemia in Chronic Phase Single Agent Asciminib, Low TKI, Elective Free Treatment - Chronic Myeloid Leukemia, Chronic Phase, Adult CML | Phase 2 | Active not recruiting | University of Alabama at Birmingham | 100 | 2022-04-22 | 2026-07-22 |
| ASTX727 and Dasatinib for the Treatment of Newly Diagnosed Philadelphia Chromosome or BCR-ABL Positive Chronic Myeloid Leukemia in Chronic Phase Dasatinib, Decitabine and Cedazuridine - Chronic Phase Chronic Myelogenous Leukemia, Philadelphia Chromosome Positive | Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 39 | 2021-10-21 | 2026-10-02 |
| A Study to Access Efficacy and Safety of P1101 in Chinese PV Patients Who Are Intolerant or Resistance to HU Ropeginterferon alfa-2b - Polycythemia Vera | Phase 2 | Active not recruiting | PharmaEssentia | 49 | 2021-10-08 | 2025-08-03 |
| HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide Busulfan, Fludarabine, Total-body irradiation - Acute Lymphoblastic Leukemia, Acute Myelogenous Leukemia | Phase 2 | Active not recruiting | Center for International Blood and Marrow Transplant Research | 300 | 2021-09-30 | 2026-03-18 |
Showing 20 of 70. Sign in to see all of them.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive (23) · Myelodysplastic Syndromes (21) · Primary Myelofibrosis (20) · Leukemia, Myeloid, Acute (18) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (18) · Leukemia, Myeloid, Chronic-Phase (15) · Lymphoma, Non-Hodgkin (11) · Polycythemia Vera (11) · Leukemia, Myelomonocytic, Chronic (10) · Hodgkin Disease (9) · Thrombocythemia, Essential (8) · Leukemia, Myeloid, Accelerated Phase (7) · Anemia, Refractory, with Excess of Blasts (6) · Leukemia, Lymphocytic, Chronic, B-Cell (6)
Hemic and Lymphatic Diseases (70) · Bone Marrow Diseases (68) · Hematologic Diseases (65) · Neoplasms (54) · Neoplasms by Histologic Type (46) · Disease Attributes (45) · Pathologic Processes (45) · Pathological Conditions, Signs and Symptoms (45) · Chronic Disease (44) · Leukemia (43) · Leukemia, Myeloid (43) · Immune System Diseases (19) · Immunoproliferative Disorders (19) · Lymphatic Diseases (19)
Cyclophosphamide (17) · Tacrolimus (10) · fludarabine (10) · Melphalan (9) · Mycophenolic Acid (9) · Whole-Body Irradiation (9) · fludarabine phosphate (9) · ruxolitinib (9) · Dasatinib (8) · Busulfan (7) · Imatinib Mesylate (7) · Methotrexate (6) · nilotinib (6) · Mesna (5) · Peripheral Blood Stem Cell Transplantation (5)
M.D. Anderson Cancer Center (9) · National Cancer Institute (NCI) (7) · City of Hope Medical Center (4) · Fred Hutchinson Cancer Center (3) · Memorial Sloan Kettering Cancer Center (3) · Bristol-Myers Squibb (2) · Center for International Blood and Marrow Transplant Research (2) · Children's Oncology Group (2) · H. Lee Moffitt Cancer Center and Research Institute (2) · PharmaEssentia (2) · St. Jude Children's Research Hospital (2) · AbbVie (1) · Baylor College of Medicine (1) · Centre Leon Berard (1) · Disc Medicine, Inc (1)
United States (55) · Germany (13) · France (10) · Italy (9) · Spain (8) · Canada (6) · Poland (6) · Australia (5) · United Kingdom (5) · Netherlands (4) · Belgium (3) · Hungary (3) · Israel (3) · South Korea (3) · Austria (2)
Elias Jabbour (3) · Brandon Triplett, MD (2) · Steven Devine, MD (2) · Alessandro Rambaldi, MD (1) · Amer Zeidan (1) · Ann Jakubowski, MD (1) · Auayporn P. Nademanee, MD (1) · Brian J Druker (1) · Daniela Zackova (1) · Dr. B. A. Adeagbo (1) · Elias Jabbour, MD (1) · Filippo Milano (1)
PMID 22915637, PMID 24092933, PMID 26432046, PMID 27760761, PMID 29723397, PMID 30501869, PMID 31553487, PMID 32040960, PMID 33049057, PMID 33513367, PMID 33609248, PMID 36564535, PMID 36600670, PMID 37042865, PMID 37129584, PMID 37308342, PMID 37344895, PMID 37422688, PMID 37517413, PMID 37592092, PMID 37611156, PMID 38033284, PMID 38423051, PMID 38744144, PMID 39250708, PMID 39387441, PMID 40313042, PMID 40330782, PMID 40523209, PMID 41671533, PMID 42253638, PMID 42306077, PMID 42448319, PMID 42616616, PMID 42784255
2015 (3), 2023 (3), P30CA015704 (2), P30CA033572 (2), U10CA032102 (2), U10CA180888 (2), 2017 (1), 2019 (1), 2025 (1), N01CM17103 (1), N01CM62201 (1), N01CM62204 (1), N01CM62207 (1), P01CA018029 (1), P30CA013330 (1)